Physician profile
Edward Kaye
NPI 1336559947
$3,626.21
in general payments reported to CMS, 2019-2025
12 companies · $2,137 in 2025
The $2,137 reported for 2025 was more than what 82% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.69 · 2021: $28.47 · 2022: $351 · 2023: $652 · 2024: $428 · 2025: $2,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,072 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,071.63 |
| Education | $144.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noctrix Health, INC. | $1,451.91 | 2025 | Nidra |
| Harmony Biosciences LLC | $1,098.98 | 2021-2025 | Wakix |
| Inspire Medical Systems, INC. | $722.37 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $129.17 | 2019-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $48.30 | 2025 | Lumryz |
| Lilly USA, LLC | $40.03 | 2025 | Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $34.28 | 2024-2025 | Voquezna |
| Fisher & Paykel Healthcare INC | $28.29 | 2024-2025 | Fisher & Paykel Healthcare |
| Takeda Pharmaceuticals U.S.A., INC. | $21.90 | 2025 | Entyvio |
| Inogen, INC. | $19.76 | 2025 | |
| Amgen INC. | $17.03 | 2022 | |
| Grifols USA, LLC | $14.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Kaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.